|
1
|
Lu XM, Zhang YM, Lin RY, Arzi G, Wang X,
Zhang YL, Zhang Y, Wang Y and Wen H: Relationship between genetic
polymorphisms of metabolizing enzymes CYP2E1, GSTM1 and Kazakh’s
esophageal squamous cell cancer in Xinjiang. World J Gastroenterol.
11:3651–3654. 2005.PubMed/NCBI
|
|
2
|
Schmale H and Bamberger C: A novel protein
with strong homology to the tumor suppressor p53. Oncogene.
15:1363–1367. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Graesslin O, Chantot-Bastaraud S,
Lorenzato M, Birembaut P, Quéreux C and Daraï E: Fluorescence in
situ hybridization and immunohistochemical analysis of p53
expression in endometrial cancer: prognostic value and relation to
ploidy. Ann Surg Oncol. 15:484–492. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Halling KC and Kipp BR: Fluorescence in
situ hybridization in diagnostic cytology. Hum Pathol.
38:1137–1144. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li WJ and Duan JX: Detecting of p53 gene
heterozygosity loss in esophageal carcinoma tissues. JZU Med Sci.
39:499–501. 2004.
|
|
6
|
Hollstein MC, Metcalf RA, Welsh JA,
Montesano R and Harris CC: Frequent mutation of the p53 gene in
human esophageal cancer. Proc Natl Acad Sci USA. 87:9958–9961.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Audrézet MP, Robaszkiewicz M, Mercier B,
et al: TP53 gene mutation profile in esophageal squamous cell
carcinomas. Cancer Res. 53:5745–5749. 1993.PubMed/NCBI
|
|
8
|
Nakamura H, Saji H, Idiris A, et al:
Chromosomal instability detected by fluorescence in situ
hybridizationin surgical specimens of non-small cell lung cancer is
associated with poor survival. Clin Cancer Res. 9:2294–2299.
2003.
|
|
9
|
Cheng ZQ, Wang XM, Shan J, et al:
Detection of p53 gene deletion in primary lung cancer by dual-FISH
technique and its clinical significance. Clin Med Chin. 26:368–371.
2010.
|
|
10
|
Uchino S, Saito T, Inomata M, Osawa N,
Chikuba K, Etoh K and Kobayashi M: Prognostic significance of the
p53 mutation in esophageal cancer. Jpn J Clin Oncol. 26:287–292.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
da Manoel-Caetano FS, Borim AA, Caetano A,
Cury PM and Silva AE: Cytogenetic alterations in chagasic achalasia
compared to esophageal carcinoma. Cancer Genet Cytogenet.
149:17–22. 2004.PubMed/NCBI
|
|
12
|
Curtis C, Harris MD and Hollstein MC:
Clinical implications of the p53 tumor suppessor gene. N Eng J Med.
329:1318–1325. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Smith DR, Ji CY and Coh HS: Prognostic
significance of p53 over expression and mutation in colorectal
adrecarcinomas. Br J Cancer. 74:216–223. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fritcher EG, Brankley SM, Kipp BR, et al:
A comparison of conventional cytology, DNA ploidy analysis, and
fluorescence in situ hybridization for the detection of
dysplasia and adenocarcinoma in patients with Barrett’s esophagus.
Hum Pathol. 39:1128–1135. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kawai T, Hiroi S, Nakanishi K, Sakurai Y
and Torikata C: Abnormalities in chromosome 17 and p53 in lung
carcinoma cells detected by fluorescence in situ hybridization.
Pathol Int. 54:413–419. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Varshney D, Zhou YY, Geller SA and Alsabeh
R: Determination of HER-2 status and chromosome 17 polysomy in
breast carcinomas comparing Hercep Test and PathVysion FISH assay.
Am J Clin Pathol. 121:70–77. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fujiwara T, Cai DW, Georges R, et al:
Therapeutic effect of a retroviral wild-type p53 expression vector
in an orthotopic lung cancer model. J Natl Cancer Inst.
86:1458–1462. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lu SM, Cheng CL and Sheng BY:
Immunohistochemical detection of p53 protein altered expression in
1364 patients with maligant tumors and its clinicopathological
significance. Chin J Cancer. 20:620–623. 2001.
|
|
19
|
Li JD, Li H and Shen ZY: Esophageal
spontaneous apoptosis and nuclear value-added antigen, relationship
with p53. Chin J Oncol. 20:415–417. 1998.
|
|
20
|
Idiris A, Madiniyet N, Hadeti B, Zhang Z,
Ilyar S and Wen H: Molecular pathological diagnosis for early
esophageal cancer in Kazakh patients. Oncol Lett. 13:549–553.
2012.
|
|
21
|
Abedi-Ardekani B, Kamangar F, Sotoudeh M,
et al: Extremely high Tp53 mutation load in esophageal squamous
cell carcinoma in Golestan Province, Iran. PLoS One. 6:e294882011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
King SI, Purdie CA, Bray SE, Quinlan PR,
Jordan LB, Thompson AM and Meek DW: Immunohistochemical detection
of Polo-like Kinase-1 (PLK1) in primary breast cancer is associated
with TP53 mutation and poor clinical outcome. Breast Cancer Res.
14:402012. View
Article : Google Scholar : PubMed/NCBI
|
